Abstract |
The recent discovery that cholecystokinin (CCK) is present in the nervous system has prompted studies that have nearly proven its neurotransmitter status. Pain modulation appears to be a major effect of CCK and proglumide, its antagonist. CCK's inhibitory effect and proglumide's potentiating effect on opiate analgesia may have clinical application; proglumide's inhibitory effect on opiate tolerance may help in management of chronic pain. More research is required before the CCK/ opiate interaction can be exploited on a large scale to relieve pain.
|
Authors | J W McRoberts |
Journal | Anesthesia progress
(Anesth Prog)
1986 Mar-Apr
Vol. 33
Issue 2
Pg. 87-90
ISSN: 0003-3006 [Print] United States |
PMID | 2872841
(Publication Type: Journal Article, Review)
|
Chemical References |
- Neurotransmitter Agents
- Receptors, Opioid
- Cholecystokinin
- Proglumide
|
Topics |
- Cholecystokinin
(analysis, antagonists & inhibitors, physiology)
- Humans
- Neurotransmitter Agents
- Pain
(drug therapy, physiopathology)
- Periaqueductal Gray
(analysis)
- Proglumide
(pharmacology)
- Receptors, Opioid
(physiology)
|